Cargando…
Data monitoring committees for clinical trials evaluating treatments of COVID-19
The first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019 and the outbreak of SARS-CoV-2 was declared a pandemic in March 2020 by the World Health Organization. This sparked a plethora of investigations into diagnostics and vaccination for SARS-CoV-2, as well as treatment...
Autores principales: | Mütze, Tobias, Friede, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833551/ https://www.ncbi.nlm.nih.gov/pubmed/32961361 http://dx.doi.org/10.1016/j.cct.2020.106154 |
Ejemplares similares
-
Establishing a data monitoring committee for clinical trials
por: LIN, Julia Y, et al.
Publicado: (2014) -
Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative
por: Calis, Karim A, et al.
Publicado: (2017) -
Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018) -
Data monitoring committees in pediatric randomized controlled trials registered in ClinicalTrials.gov
por: Machado, Tiago, et al.
Publicado: (2023) -
Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
por: Beyersmann, Jan, et al.
Publicado: (2021)